GIM
NBIX icon

Glenmede Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Glenmede Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$11.6M Sell
82,577
-1,613
-2% -$219K 0.06% 319
2025
Q2 		$10.6M Buy
+84,190
New +$9.65M 0.05% 344

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Glenmede Investment Management's NBIX Position: Q3 2025 in Review

Glenmede Investment Management reduced its Neurocrine Biosciences (NBIX) stake by 1.9% in Q3 2025, selling an estimated $219K and leaving 82,577 shares worth $11.6M. The position accounts for 0.06% of the portfolio, ranked #319.

Glenmede Investment Management first reported a position in NBIX in Q2 2025 and has held it in 2 quarters since. 650 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Glenmede Investment Management held 82,577 shares of Neurocrine Biosciences worth $11.6M as of Q3 2025.
  • Glenmede Investment Management sold 1,613 Neurocrine Biosciences shares in Q3 2025, an estimated $219K.
  • Neurocrine Biosciences made up 0.06% of Glenmede Investment Management's portfolio in Q3 2025, its #319 holding.
  • Glenmede Investment Management first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 2 quarters since.
  • 650 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.